Equillium, Inc. (EQ)

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Equillium, Inc. (NASDAQ:EQ) Given Consensus Recommendation of “Moderate Buy” by Analysts

EQ Works Expands Multi-Year Partnership with Leading Canadian Publisher to Include SaaS License for ClearLake

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript

Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1

Equillium to Participate in the 2026 Jefferies Global Healthcare Conference